Quick answer: Neuroinflammation — activation of the CNS innate immune system via microglia and astrocytes — is now recognized as a central mechanism in chronic pain, depression, Alzheimer’s disease, Parkinson’s disease, post-COVID syndrome, and traumatic brain injury. Unlike acute pain (nociception), chronic pain involves central sensitization: a state of amplified neural signaling where the CNS itself becomes the generator of pain, independent of ongoing tissue injury.
The Neurobiology of Chronic Pain: Central Sensitization and Wind-Up
Acute pain serves a protective function — it signals tissue damage and promotes protective behaviors. Chronic pain is fundamentally different: it persists beyond tissue healing, involves structural and functional changes in the pain-processing nervous system, and can be self-perpetuating independent of peripheral injury. Woolf (2011, Annals of Internal Medicine) defined three categories of chronic pain: nociceptive (ongoing tissue damage — arthritis, cancer pain), neuropathic (damage to the somatosensory nervous system — diabetic neuropathy, post-herpetic neuralgia, complex regional pain syndrome), and nociplastic (sensitized pain processing without identifiable tissue or nerve damage — fibromyalgia, IBS, tension headache, non-specific chronic widespread pain).
Wind-up and central sensitization: Repeated C-fiber stimulation produces progressively amplified spinal cord responses — “wind-up” — via NMDA receptor activation by glutamate and substance P. This is the foundation of central sensitization. Woolf and Salter (2000, Science) characterized central sensitization as: lowered activation thresholds (allodynia — pain from normally innocuous stimuli like light touch), expanded receptive fields (pain spreading beyond the original injury site), and prolonged after-discharges. Once established, central sensitization can persist after the original stimulus is removed — the nervous system has undergone a form of “pain memory.”
Neuroimaging has transformed our understanding: Woolf and colleagues used fMRI to demonstrate that fibromyalgia patients show amplified neural responses to the same pressure stimuli compared to healthy controls — and the regions activated include not just somatosensory cortex but the anterior cingulate cortex (emotional pain processing), insula (interoception), and prefrontal cortex (cognitive pain modulation). Chronic pain is literally encoded in different neural circuits than acute pain.
Microglia: The CNS Immune Cells Driving Neuroinflammation
Microglia constitute approximately 10–15% of all CNS cells and are the resident macrophages of the brain and spinal cord — derived from yolk-sac progenitors that colonize the CNS embryologically (distinct from peripheral monocytes). In their surveillance state, microglia constantly extend and retract processes, monitoring synaptic activity, clearing debris (synaptic pruning), and responding to injury signals. When activated by pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), or cytokines from peripheral inflammation (via blood-brain barrier disruption), microglia shift to inflammatory M1-like phenotype, releasing: TNF-α, IL-1β, IL-6, prostaglandins (PGE2), nitric oxide (iNOS-derived), reactive oxygen species, and glutamate — all of which sensitize adjacent neurons and lower pain thresholds.
Ji et al. (2016, Nature Reviews Neuroscience) demonstrated that spinal cord microglia are essential for neuropathic pain — microglial inhibition with minocycline blocked the development of allodynia in nerve-injury models. Importantly, peripheral inflammation — gut-derived LPS, systemic cytokines, metabolic endotoxemia — can activate spinal and brain microglia via the blood-brain barrier, explaining why chronic systemic inflammation (from gut dysbiosis, obesity, or autoimmune disease) correlates with central pain sensitization and depression.
Inflammation-Pain-Depression: The Cytokine Hypothesis of Psychiatric Disease
Irwin and Miller (2007) and subsequent work established that inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-α) produce “sickness behavior” — fatigue, social withdrawal, anhedonia, cognitive slowing, sleep disruption, increased pain sensitivity — that is phenomenologically identical to depression. This is not coincidental: these behaviors evolved as adaptive responses to infection (conserving energy, reducing social contact to prevent pathogen spread). The problem is chronic low-grade inflammation — from dysbiosis, metabolic disease, psychological stress, or environmental exposures — maintaining this sickness behavior state indefinitely.
Miller et al. (2009, Archives of General Psychiatry) found that basal plasma IL-6 and CRP predicted antidepressant non-response — patients with high inflammatory markers had poor response to SSRIs but good response to anti-inflammatory interventions. The landmark Raison et al. (2013, JAMA Psychiatry) RCT of infliximab (TNF-α antibody) in treatment-resistant depression showed no overall antidepressant effect — but in patients with elevated baseline CRP (>5 mg/L), infliximab produced significant antidepressant response. This is precision psychiatry: inflammatory biomarkers identifying the subgroup who will respond to anti-inflammatory treatment.
The gut-brain axis is central to this story: the vagus nerve (80% afferent fibers carrying gut signals to the brain) communicates microbiome state to the CNS. Gut bacteria produce 95% of the body’s serotonin (as enterochromaffin cells respond to serotonin produced by bacteria), GABA (Lactobacillus species produce GABA — Bravo et al. 2011 demonstrated Lactobacillus rhamnosus JB-1 reduced anxiety and altered GABA receptor expression in mice in a vagus-dependent manner), and tryptophan metabolites that cross the blood-brain barrier to influence neurotransmitter synthesis. Fecal microbiota transplant (FMT) from depressed human donors to germ-free rats produced depressive behavior (Kelly et al., 2016, Journal of Psychiatric Research), establishing causality.
Neuroinflammation Testing: Biomarkers That Matter
High-sensitivity CRP (hsCRP): The most widely available marker of systemic inflammation. Values below 1.0 mg/L indicate low cardiovascular and inflammatory risk; 1.0–3.0 mg/L is intermediate; above 3.0 mg/L is high risk (independent of cardiac disease, this level predicts treatment-resistant depression and chronic pain amplification). Values above 10 mg/L suggest acute infection or significant active inflammatory disease. hsCRP is not CNS-specific but is highly accessible and clinically useful.
Erythrocyte Sedimentation Rate (ESR): Less specific than hsCRP but clinically useful — elevated in autoimmune conditions (RA, lupus, polymyalgia rheumatica), infections, and malignancy. A normal ESR with elevated hsCRP suggests metabolic inflammation; elevated ESR with elevated hsCRP suggests more significant active inflammatory disease.
Interleukin-6 (IL-6): Available as serum measurement; more directly measures pro-inflammatory cytokine activity than acute-phase reactants. Elevated IL-6 correlates with central sensitization severity in fibromyalgia (Üçeyler et al. 2011), depression severity, and Alzheimer’s progression (Swardfager 2010 meta-analysis, Biological Psychiatry: significant IL-6 elevation in AD brain).
TNF-α and neopterin: Specialty labs; TNF-α is the master pro-inflammatory cytokine — elevated in autoimmune disease, chronic infections, and metabolic disease. Neopterin (produced by macrophages in response to IFN-γ) is a sensitive marker of macrophage/microglia activation useful in tracking neuroinflammatory burden.
PET neuroimaging with TSPO ligands: Research gold standard for in-vivo microglial activation — Translocator Protein (TSPO, formerly peripheral benzodiazepine receptor) is upregulated in activated microglia. Studies using [11C]PK11195 and newer TSPO ligands have documented elevated microglial activation in fibromyalgia (Albrecht 2019, Brain), major depression (Holmes 2018), Alzheimer’s disease, Parkinson’s disease, and chronic fatigue syndrome/ME-CFS (Nakatomi 2014, Journal of Nuclear Medicine). Not available clinically, but has transformed our understanding of neuroinflammation in these conditions.
Evidence-Based Anti-Neuroinflammatory Interventions
Omega-3 fatty acids (EPA/DHA): Directly incorporated into neuronal membranes, reducing arachidonic acid-derived pro-inflammatory eicosanoid production. EPA and DHA serve as substrates for specialized pro-resolving mediators (SPMs) — resolvins (RvD1, RvD2, RvE1), protectins (PD1/neuroprotectin D1), and maresins — which actively terminate inflammation by promoting macrophage/microglia phenotype switch from M1 (inflammatory) to M2 (anti-inflammatory, tissue-repairing). Rapaport et al. (2016): EPA 4.4g vs. placebo for major depressive disorder showed significant improvement (effect size 0.60). A 2019 meta-analysis (Mocking et al., Translational Psychiatry, n=19 RCTs): omega-3 supplementation significantly improved depression outcomes, with EPA-dominant formulations (>60% EPA) showing the most consistent effect. For pain specifically, a Maroon and Bost (2006) pilot showed omega-3 supplementation at 2.4g/day reduced pain scores in chronic neck/back pain comparable to ibuprofen with COX-inhibitory mechanism confirmed via prostaglandin reduction.
Palmitoylethanolamide (PEA): An endocannabinoid-related molecule produced endogenously by neurons and immune cells in response to pain and inflammation. PEA activates PPAR-α receptors, inhibiting NF-κB-mediated microglial activation, reducing mast cell degranulation (critical in neurogenic inflammation), and downregulating TRPV1 channels involved in pain transduction. A 2016 meta-analysis by Paladini et al. (Pain Physician, n=1,170 patients across 11 studies, doses 300–1200mg/day): PEA significantly reduced pain scores across chronic pain conditions (VAS reduction of 2.67 points vs. control) with excellent tolerability. Keppel-Hesselink’s systematic review (2015): consistently effective in diabetic neuropathy, fibromyalgia, and chronic pelvic pain with no drug interactions. Ultra-micronized PEA (600mg BID or 300mg TID) is the best-studied formulation with enhanced bioavailability.
Curcumin (BCM-95 / Longvida formulations): Multiple mechanisms relevant to neuroinflammation: NF-κB inhibition (reducing COX-2, iNOS, TNF-α, IL-1β, IL-6 expression), direct inhibition of NLRP3 inflammasome activation (Wen et al. 2011, Journal of Immunology), BDNF upregulation, and amyloid-β aggregation inhibition. Standard curcumin is poorly bioavailable (<1% oral absorption) — lipid-formulated BCM-95 and Longvida (phospholipid complex) achieve 6-8x and 65x higher bioavailability respectively. Ng et al. (2006, American Journal of Epidemiology): Asian elderly with higher curry consumption scored significantly better on cognitive tests. Lopresti et al. (2014, Phytotherapy Research, RCT n=56): BCM-95 comparable to fluoxetine for MDD with additional anxiolytic effect. For chronic pain: Ryan et al. (2008): 2g turmeric equivalent significantly reduced post-exercise muscle damage vs. NSAID comparator.
Low Dose Naltrexone (LDN) for neuroinflammation: Distinct from its opioid-antagonist mechanism, LDN at 1.5–4.5mg has glial modulatory effects — binding to Toll-like receptor 4 (TLR4) on microglia at non-opioid receptor sites, blocking LPS-induced microglial activation and reducing pro-inflammatory cytokine production. This mechanism was characterized by Hutchinson et al. (2008, European Journal of Neuroscience). Younger and Mackey (2009, Pain Medicine, n=10 fibromyalgia women, crossover RCT): LDN 4.5mg produced 30% reduction in fibromyalgia symptom severity vs. placebo. Younger et al. (2013, Pain Medicine, n=31 fibromyalgia, RCT): LDN significantly reduced pain (reduction in VAS by −1.42 vs. −0.62 placebo), and pain reduction correlated with reduced erythrocyte sedimentation rate — confirming anti-inflammatory mechanism. Patient-reported satisfaction surveys show >60% of fibromyalgia patients report significant benefit.
Magnesium (glycinate or threonate for CNS penetration): NMDA receptor antagonist — physiological magnesium blocks the NMDA receptor channel in a voltage-dependent manner. In central sensitization, NMDA receptor hyperactivation perpetuates wind-up and allodynia; magnesium deficiency removes this physiological block. Rondón et al. (2019): IV magnesium infusion significantly reduced pain sensitivity (von Frey threshold testing) in fibromyalgia patients. Oral magnesium glycinate 400mg daily or magnesium-L-threonate (Magtein) — which penetrates the blood-brain barrier more effectively (Slutsky 2010, Neuron: 15% higher CSF magnesium and cognitive improvement in aged rats) — are clinically preferred.
Post-COVID Neuroinflammation and Chronic Fatigue
Post-Acute Sequelae of SARS-CoV-2 (PASC / Long COVID) with neurological manifestations — brain fog, fatigue, headache, cognitive impairment, widespread pain — has brought neuroinflammation into mainstream clinical awareness. Multiple mechanistic studies have documented: persistent microglial activation on TSPO-PET imaging (Nakatomi 2021 data), elevated neuroinflammatory biomarkers (IL-6, neopterin, GFAP, neurofilament light chain — NfL — a marker of axonal damage), mast cell activation contributing to neurogenic inflammation, and mitochondrial dysfunction in neurons and immune cells (similar to ME-CFS pathophysiology).
Therapeutically, functional medicine approaches with the most rationale for long-COVID neuroinflammation: LDN (TLR4 antagonism and microglial modulation), low-histamine diet + mast cell stabilizers (see our MCAS article), mitochondrial support (see our longevity stack article), omega-3 and PEA for microglial modulation, and vagal nerve stimulation (non-invasive transcutaneous vagus nerve stimulation — taVNS — has emerging evidence in post-COVID and ME-CFS via cholinergic anti-inflammatory pathway).
Neuroinflammation at The Private Practice
At The Private Practice, we evaluate chronic pain and neuroinflammation through an integrative lens — measuring hsCRP, IL-6, gut permeability markers, and microbiome health alongside conventional workup. Our treatment approaches connect across our work in gut-immune restoration, MCAS, HPA axis/stress, and sleep optimization — because neuroinflammation does not exist in isolation.
Frequently Asked Questions
What is the difference between neuropathic pain and fibromyalgia?
Neuropathic pain involves identifiable damage to the somatosensory nervous system — a damaged peripheral nerve, dorsal root ganglion, or central pain pathway. Examples include diabetic peripheral neuropathy (axonal degeneration from hyperglycemia), post-herpetic neuralgia (nerve damage from varicella-zoster reactivation), and complex regional pain syndrome (aberrant sympathetic nervous system activation following injury). Fibromyalgia is classified as “nociplastic pain” — central sensitization with amplified pain processing without identifiable nerve or tissue damage. The distinction matters for treatment: neuropathic pain responds to gabapentinoids, SNRIs, and topical agents that target peripheral sensitization; fibromyalgia responds better to LDN, anti-inflammatory approaches, sleep restoration, graded exercise, and central sensitization-targeting therapies like mindfulness and pain neuroscience education.
Can diet reduce neuroinflammation and chronic pain?
Yes — dietary patterns have measurable effects on neuroinflammation. Anti-inflammatory dietary approaches (Mediterranean, whole-food plant-forward) reduce hsCRP, IL-6, and TNF-α — the same cytokines driving central sensitization. Specific interventions: eliminating ultra-processed foods and added sugars (which activate NF-κB via AGE formation and TLR4 activation); increasing omega-3 intake from fatty fish (EPA/DHA) and ground flaxseed (ALA → EPA/DHA conversion, ~10% efficiency); increasing polyphenol intake from berries, dark chocolate, turmeric, and green tea (EGCG) — these compounds directly inhibit NF-κB and NLRP3 inflammasome; eliminating food triggers identified through elimination-challenge (particularly gluten in Hashimoto’s and widespread pain). The gut-pain connection means that dietary approaches reducing gut permeability and dysbiosis (high-fiber, fermented foods) will secondarily reduce central neuroinflammation.
What is PEA (palmitoylethanolamide) and is it safe?
Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide produced endogenously by neurons, immune cells, and other tissues in response to pain and inflammation. It is not cannabis-derived or psychoactive — it works through PPAR-α receptors and interacts with the endocannabinoid system without directly binding CB1 or CB2 receptors. It has been in clinical use in Europe since the 1970s and has an exceptional safety profile across decades of use and over 30 human clinical trials. PEA has no known drug interactions, no addictive potential, and is well tolerated even at doses up to 1,800mg/day. It can be safely combined with conventional pain medications, though it may allow for dose reduction of NSAIDs and other analgesics. It is appropriate for long-term use in chronic conditions.
How does sleep affect chronic pain and neuroinflammation?
Sleep deprivation is both a cause and consequence of chronic pain — creating a bidirectional vicious cycle. Mechanistically: sleep deprivation increases microglial activation (Hurtado-Alvarado 2016 — 5 days sleep restriction produced significant microglial morphological changes in the hippocampus of rats), elevates pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 all increase with sleep restriction — Irwin 2016 meta-analysis), impairs glymphatic clearance of metabolic waste (Nedergaard 2012 — glymphatic flow is 60% more active during sleep), and reduces endogenous opioid activity (Edwards 2009 demonstrated sleep deprivation decreased μ-opioid receptor availability in pain-processing brain regions). In fibromyalgia patients, improving sleep quality alone (via CBT-I, addressing sleep apnea, LDN at bedtime) produces meaningful pain reduction — often more than adding another analgesic.
To schedule a comprehensive neuroinflammation and chronic pain evaluation at The Private Practice, call (810) 206-1402 or visit theprivatepractice.co. We provide thorough inflammatory biomarker assessment, gut-brain axis evaluation, and evidence-based anti-neuroinflammatory protocols to address the root causes of chronic pain, fatigue, and cognitive dysfunction.